Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- Chronic fatigue from ME/CFS, Long COVID, and post-viral exhaustion often resists standard care, so many patients explore NAD+ for mitochondrial energy support.
- NAD+ is a coenzyme essential for ATP production, and levels decline with age. Disturbed NAD+ metabolism appears in ME/CFS, which supports a rationale for supplementation.
- Among delivery methods, oral NADH combined with CoQ10 has the strongest clinical evidence for fatigue relief. IV NAD+ lacks robust trials and carries higher side-effect risks.
- Recent 2026 reviews show no NAD+ precursor significantly improves perceived fatigue across large groups, so patients benefit from individualized, medically supervised protocols.
- Patients seeking safe, evidence-informed NAD+ therapy should work with a qualified provider. Schedule a consultation at Mirror Plastic Surgery to explore personalized options.
How NAD+ Supports Cellular Energy and Fatigue
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It shuttles electrons during cellular respiration and helps convert nutrients into ATP, the energy currency that powers nearly every biological process. When NAD+ levels fall, mitochondria struggle to produce energy efficiently.
NAD+ therapy adds nicotinamide adenine dinucleotide or its precursors to support cellular energy production. For chronic fatigue, the goal is to restore declining NAD+ levels and support mitochondrial function. Clinical evidence for symptom relief remains mixed, and most use is off-label.
NAD+ levels decline by about 50% between ages 40 and 60. This drop correlates with mitochondrial dysfunction and impaired DNA repair. In ME/CFS, researchers have mapped disturbances in NAD+/kynurenine metabolism, which supports a mechanism-based case for NAD+ precursor therapy. NAD+ is often grouped with peptides in wellness marketing, but it is technically a coenzyme, not a peptide, and that distinction matters when evaluating products and protocols.
You can explore more foundational science on the Mirror Plastic Surgery NAD overview.
NAD+ Therapy Routes for Chronic Fatigue: Comparing Options
Four primary delivery routes exist for NAD+ therapy. The right option depends on your health status, treatment goals, and the level of medical supervision. Many clinics use a combination approach, with an initial IV phase followed by subcutaneous injections or oral precursors for maintenance.
| Option | How It Works | Key Pros | Key Cons |
|---|---|---|---|
| IV NAD+ Infusion | High-dose NAD+ delivered into the bloodstream over 2–4 hours in a clinic, with standard doses of 250–750 mg per infusion. | Highest immediate bioavailability and rapid increase in blood NAD+ levels. | Invasive, time-consuming, and requires clinic visits. A 2026 real-world study reported that every IV NAD+ recipient experienced moderate-to-severe adverse effects including nausea, chest pressure, and elevated heart rate. Evidence for chronic fatigue remains anecdotal, with no robust randomized trials. |
| Subcutaneous (SubQ) Injections | Lower-dose NAD+ self-administered at home under medical supervision, usually 100–200 mg injected two to three times per week. | Convenient and more affordable than IV, with sessions that take minutes. Often used for maintenance protocols. | Requires training and produces a less dramatic effect than IV. Human data for subcutaneous NAD+ remain largely anecdotal, and no published head-to-head comparisons with IV therapy exist. |
| Oral Precursors (NMN, NR, NADH) | Daily supplements that the body converts into NAD+, including nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and NADH. | Easy, non-invasive, and the most extensively studied route in clinical trials. Oral NMN at 1 g daily raises blood NAD+ about 40–60% above baseline. | Oral NAD+ itself has only 5–15% bioavailability because gastric acid degrades it. Evidence for fatigue relief is mixed, and some precursors show more promise than others. |
| Transdermal Patches | NAD+ delivered through the skin over several hours as a needle-free option. | Steady release and easy, non-invasive use. | No convincing published human trials exist. Intact skin blocks NAD+ because of its molecular size and charge, so this route currently has the weakest support. |
Book an appointment with Ellie to discuss which NAD+ delivery method fits your health history, goals, and lifestyle.
Current Research on NAD+ for Chronic Fatigue
Research on NAD+ for chronic fatigue paints a nuanced picture. Some approaches show promise, while others raise more questions than answers.
Oral NADH: Early controlled evidence comes from a 1999 placebo-controlled crossover trial by Forsyth and colleagues. The study gave 26 ME/CFS patients 10 mg of oral NADH daily for four weeks. About 31% of patients improved on NADH compared with about 8% on placebo, based on self-reported symptom scores.1 A stronger signal appeared in a 2021 randomized, double-blind, placebo-controlled trial by Castro-Marrero and colleagues that enrolled 207 ME/CFS patients. Daily use of 200 mg of CoQ10 plus 20 mg of NADH for 12 weeks significantly reduced perceived cognitive fatigue and improved health-related quality of life compared with placebo.1
Oral NR and NMN: Newer trials are less encouraging for fatigue. A 24-week randomized trial of adults with Long COVID (Wu 2025) used high-dose NR at 2,000 mg per day. The protocol tripled blood NAD+ but did not significantly improve fatigue, cognition, sleep, anxiety, or depression compared with placebo.1 A 2026 systematic review and network meta-analysis by Gao et al. in Frontiers in Nutrition pooled 27 studies and 1,599 participants. The authors concluded that no NAD+ precursor, including NR, NMN, NADH, or nicotinamide, significantly improved perceived fatigue or sleep quality across broad populations.1
IV NAD+: Researchers have not yet completed randomized outcome trials of IV NAD+ for ME/CFS or Long COVID. The only published human pharmacokinetic study, Grant et al. (2019), found that plasma NAD+ did not begin rising until about two hours into a six-hour infusion. The study also showed significant urinary excretion of NAD+ metabolites, which suggests that much of the infused NAD+ is broken down and excreted rather than taken up by tissues.
The overall pattern shows the strongest evidence for oral NADH in combination with CoQ10. IV NAD+ remains popular, but current proof lags behind its marketing. The 2026 Gao et al. review supports a precision-based approach that considers outcome type, dosage, and patient characteristics instead of a single universal protocol.
Safety, Side Effects, and Regulatory Considerations
Side effects of NAD+ therapy vary by route. Reported side effects of NAD+ injections include nausea, flushing, headache, soreness or redness at the injection site, dizziness, and chest tightness during IV infusion. Most reactions are mild and resolve within one to three hours. Side effects depend on dose and infusion rate, and slowing an IV drip often reduces discomfort. Rare but serious risks include allergic reactions, phlebitis, rapid heart rate, and chest pain that require immediate medical care.
NAD+ and its precursors are not FDA-approved for treating chronic fatigue. Mirror Plastic Surgery notes that peptides are not FDA-regulated and stresses sourcing from reputable providers with batch testing, which highlights that federal guarantees of quality and purity do not apply. Clinics should disclose whether their compounding pharmacy is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility.
NAD+ therapy requires caution or is contraindicated in pregnant or breastfeeding women, patients with active cancer without oncology approval, those with severe kidney or liver disease, and individuals on medications with potential interactions. The FDA has received adverse event reports tied to injectable NAD+ compounded from food-grade instead of sterile-grade ingredients. These reports include severe chills, vomiting, and reactions consistent with endotoxin contamination, which reflect the risks of unsupervised sourcing.
Medical supervision with baseline lab testing for liver function, metabolic markers, and a detailed health history meaningfully reduces these risks.
Choosing an NAD+ Therapy Plan for Chronic Fatigue
No single NAD+ option works for every person with chronic fatigue. A sound decision framework weighs evidence strength, your health status, convenience, and the quality of medical oversight. Fatigue functions as a symptom rather than a standalone diagnosis. Common treatable causes include sleep apnea, anemia, thyroid disease, depression, and medication side effects, and clinicians should evaluate these before attributing fatigue to NAD+ deficiency.
Before starting any NAD+ protocol, ask prospective providers:
- What baseline lab tests do you recommend to rule out other causes of my fatigue?
- What is your experience treating chronic fatigue, ME/CFS, or Long COVID?
- How do you source your NAD+ and peptides, and can you verify their quality and purity?
- What is your protocol for adjusting dosage or managing side effects?
- How do you define success, and what is your follow-up process?
A provider who answers these questions clearly and specifically offers a safer setting for a therapy that carries real clinical variables.
Complementary Peptides Often Paired With NAD+
NAD+ usually functions as one part of a broader fatigue protocol. Other peptides sometimes join it to address different aspects of the underlying biology.
BPC-157 (Body Protection Compound-157) has been studied in animal models for effects on mitochondrial ATP production and pro-inflammatory cytokine modulation. These mechanisms relate to the cellular energy deficits seen in chronic fatigue. Researchers have not yet completed Phase III randomized controlled trials of BPC-157 for chronic fatigue in humans, so its effectiveness for fatigue remains unproven in controlled human studies.
MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and has attracted research interest in ME/CFS. A 2025 review by Klimas et al. outlined its potential to address core bioenergetic failures. Exogenous administration at pharmacologic doses has not yet been evaluated in human clinical trials for this indication, and the FDA’s 2026 review found no clinical studies or human exposure data for administered MOTS-c.
A personalized combination protocol may offer broader support than NAD+ alone when a qualified clinician designs and monitors it. Ongoing tracking of outcomes, dose adjustments, and early identification of adverse responses are essential.
Book an appointment with Ellie at Mirror Plastic Surgery to explore whether a tailored peptide protocol fits your situation.
Mirror Plastic Surgery’s Medically Supervised NAD+ Care
Outcomes from NAD+ therapy often depend on who oversees the protocol.1 Personalized assessment and careful follow-up create a safer and more effective experience than high-volume or unsupervised approaches.
Mirror Plastic Surgery is a concierge practice in St. Petersburg and Tampa, Florida, that offers advanced, medically supervised peptide therapy. Ellie Pranckevicius, FNP-BC, a board-certified Family Nurse Practitioner, leads peptide protocols. Her background bridges advanced clinical medicine and aesthetic care. Ellie earned her Bachelor’s in Health Science from Boston University, completed an aesthetics licensure program, and obtained both her Bachelor’s and Master’s in Nursing from the University of South Florida. Four years in the Neuroscience ICU at Tampa General Hospital gave her deep, practical insight into physiology, metabolic health, and recovery, which directly informs how she evaluates and manages complex fatigue.
The practice follows a guiding philosophy of safety first, function second, and aesthetics third. A comprehensive 30–60 minute consultation reviews medical history, current symptoms, and health goals. In-depth lab analysis looks for root causes and rules out treatable contributors to fatigue such as thyroid dysfunction, anemia, or hormonal imbalance. The team sources peptides from reputable providers with rigorous batch testing, which supports quality and purity beyond what most online vendors can offer. Ongoing concierge support is available by text or telemedicine, and services are accessible in person in Tampa and remotely across the United States.
If you want to explore NAD+ therapy with a team that prioritizes safety and measurable results, book an appointment with Ellie at Mirror Plastic Surgery.
Common Misconceptions About NAD+ Therapy
- Myth: NAD+ is a quick fix for fatigue. Results vary and usually require consistent treatment over weeks.1 Most patients do not feel dramatic changes after a single NAD+ shot, and effects typically build over two to six weeks of consistent dosing.1
- Myth: IV NAD+ is the only effective option. Oral NADH currently has the most clinical evidence for ME/CFS, and SubQ injections may help some patients maintain benefits.
- Myth: All NAD+ products are the same. Quality and purity vary widely. One study found that 76% of NAD+ supplements failed to meet label claims, and unregulated online sources pose contamination and dosing risks.
- Myth: NAD+ is a peptide. NAD+ is a coenzyme, even though wellness marketing often groups it with peptides.
Frequently Asked Questions
Is NAD+ Therapy Effective for Chronic Fatigue Syndrome?
Evidence for NAD+ in ME/CFS remains mixed. NAD+ plays a central role in mitochondrial ATP production, and researchers have identified NAD+/kynurenine metabolism disturbances in ME/CFS. Large-scale clinical proof is still lacking. Small studies show benefit for oral NADH, especially when combined with CoQ10, while recent NR and NMN trials have not demonstrated significant fatigue improvement over placebo. IV NAD+ lacks robust clinical trials. The 2026 Gao et al. systematic review found that no NAD+ precursor significantly improved perceived fatigue across 27 studies. A medically supervised evaluation offers the best starting point before committing to any protocol.
What Are the Side Effects of NAD+ Therapy?
Common side effects include nausea, flushing, headache, and soreness or redness at injection sites. Rapid IV infusion can cause chest tightness, elevated heart rate, and lightheadedness. These effects are usually dose- and rate-dependent and often improve when the infusion slows or ends. Serious reactions, including allergic responses, phlebitis, and chest pain, are rare but possible and require immediate medical attention. Subcutaneous and intramuscular injections generally cause fewer systemic side effects than IV infusion because the body absorbs NAD+ more gradually. Oral precursors are the best-tolerated route in published studies.
How Long Does It Take to See Results from NAD+ Therapy?
Response time varies by individual, delivery route, and protocol design. Subcutaneous injection protocols often show subtle shifts in energy in weeks one to two, clearer mental focus in weeks three to four, and more noticeable cumulative effects by week six or later.1 IV therapy may produce faster initial changes for some patients, although this pattern does not guarantee long-term benefit.1 Oral precursors usually require consistent daily use over eight to twelve weeks to maintain higher blood NAD+ levels.1 Patients who expect overnight results from any route often feel disappointed.1
Can I Take NAD+ Orally Instead of IV?
Yes. Oral precursors such as NR, NMN, and NADH are available and have clinical trial data. NADH has the most evidence for chronic fatigue, especially when combined with CoQ10. NR reliably raises blood NAD+ levels but has not shown significant fatigue improvement over placebo in recent trials. NMN shows dose-dependent improvements in endurance-related performance but not in perceived fatigue. Oral NAD+ itself is poorly absorbed because the gastrointestinal tract degrades the molecule, so most products use precursors instead of NAD+ directly. A clinician can help determine which precursor and dose best fit your needs.
Is NAD+ Therapy FDA-Approved?
NAD+ and its precursors are not FDA-approved for treating chronic fatigue or any specific disease. Injectable NAD+ is a compounded substance regulated under pharmacy compounding rules rather than as an approved drug. Oral forms are sold as dietary supplements under DSHEA, so the FDA does not review them for safety or effectiveness before sale. NR received FDA GRAS (Generally Recognized as Safe) status in 2016 for use as a dietary supplement ingredient, which differs from drug approval for a medical indication. This regulatory status reinforces the need to source products through medically supervised providers with verified batch testing.
This article is for educational purposes and does not replace medical advice. NAD+ therapy is not FDA-approved for chronic fatigue. Results vary. Always consult a qualified healthcare provider.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
